Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Secondary Real-world Data Study of Pediatric and Adult Participants With Thrombotic Microangiopathy (TMA) After Hematopoietic Stem Cell Transplant (HSCT)

NCT07732361 is registered in ClinicalTrials.gov with Alexion Pharmaceuticals, Inc. as lead sponsor.

NCT NCT07732361
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07732361 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Secondary Real-world Data Study of Pediatric and Adult Participants With Thrombotic Microangiopathy (TMA) After Hematopoietic Stem Cell Transplant (HSCT)
Lead sponsor
Alexion Pharmaceuticals, Inc.
Phase
Observational
Overall status
Completed
Start date
January 22, 2025
Completion date
March 31, 2026
Enrollment
307 (actual)
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

hematopoietic stem cell transplant, thrombotic microangiopathy